101
Participants
Start Date
September 16, 2019
Primary Completion Date
March 23, 2023
Study Completion Date
June 27, 2025
Drug: Carfilzomib + Dexamethasone
"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
Drug: Carfilzomib + Lenalidomide + Dexamethasone
"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
Valentis Cancer Hospital, Meerut
Deenanath Mangeshkar Hospital and Research Centre, Pune
Apollo Hospital, Hyderabad
M S Ramaiah Memorial Hospital, Bangalore
Cytecare Cancer Hospitals, Bengaluru
K L E S Dr Prabhakar Kore Hospital and Medical Research Centre, Belagavi
Cancer Institute WIA, Chennai
Thangam Cancer Centre, Namakkal
Government Medical College, Kozhikode
Aster Medcity, Kochi
Yashoda Hospital, Hyderabad
Tata Memorial Hospital, Mumbai
Mumbai Oncocare Center, Mumbai
Navsanjeevani Hospital, Nashik
Heath Care Group Manavata Cancer Centre, Nashik
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry
Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata
Lead Sponsor
Amgen
INDUSTRY